A c c e p t e d M a n u s c r i p t
INTRODUCTION
In recent years, cardiovascular disease has emerged as a major cause of morbidity and mortality in human immunodeficiency virus-(HIV-) infected patients (1, 2) .
Prolongation of the QTc interval on the electrocardiogram surface (ECG) indicates an increase in ventricular repolarization time and represents a major risk for polymorphous ventricular tachycardia (Torsades de Pointes) and sudden arrhythmic death (3, 4) .
The prevalence of prolonged QTc in HIV patients compared with HIV-uninfected subjects has increased (5) (6) (7) . Acquired QT prolongation is more prevalent than the congenital form in HIV-positive patients and has been associated with HIV-associated autonomic dysfunction (8) , hepatitis C infection (7) and several drugs including methadone and highly active antiretroviral therapy (HAART) (5) (6) (7) (8) (9) (10) (11) (12) .
Methadone maintenance therapy is recommended as a safe and effective treatment for reducing illicit opioid use and promoting longer retention in treatment of opioiddependent HIV patients. However, cases of prolongation of the QTc interval and Torsades de Pointes in HIV patients receiving high doses of methadone have been reported (13) (14) (15) . The mechanism underlying this increase is related to the inhibitory action of methadone on the hERG voltage-gated potassium channel encoded by the human ether a-go-go related gene (hERG) (16) 
Nevertheless, no cohort studies evaluating the QTc interval in opioid-dependent HIVinfected patients on methadone maintenance treatment have been reported. Owing to the large number of HIV patients exposed to methadone (17) and the fact that it is not possible to predict the risk of QT interval prolongation in a given individual, further studies are required to identify the risk factors associated with long QTc interval so as to design prevention strategies and reduce the risk of Torsades de Pointes in this specific group of HIV patients.
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METHODS
This cross-sectional study included HIV-infected intravenous drug users who met the criteria for DSM-IV-TR opioid dependence disorder. Patients were controlled at a multidisciplinary drug abuse outpatient center in Barcelona (CAS-Barceloneta) where they received simultaneous treatment for both HIV and opioid dependence.
Subjects were informed and signed a consent form prior to being admitted to the methadone program. More details regarding the work of the CAS-Barceloneta are published elsewhere (18, 19) .
Patients with any cardiac disease, drug-positive urine test, serum electrolyte abnormalities and changes in their antiretroviral therapy or methadone doses in the last two months were excluded.
Following routine clinical practice for patients on the methadone maintenance program, a 12-lead ECG at rest was recorded just 24 hours after the last supervised oral methadone administration. All ECGs were recorded using the same device (Agilent®, Model: M17772A; Serial: CND4750784), printed at a paper speed of 25 mm/s, amplified to 10mm/mV and recorded during the morning (between 9 am and 1 pm).
Heart rate and QT interval in lead II were measured by a senior consultant specialist in internal medicine. The QT interval was corrected (QTc) by heart rate using Bazett's formula (20) .
In addition to the sex-adjusted QTc thresholds, we used a recently updated sexindependent categorical threshold of QTc >450 ms was used for QTc interval by Jules Levin on August 13, 2013 http://cid.oxfordjournals.org/
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Patients´ general characteristics and medical history were extracted from a database used in the routine care of these patients.
HAART was composed of one of the following combinations: (1) a boosted protease inhibitor (PI) plus 2 nucleoside reverse-transcriptase inhibitors (NRTIs), (2) The QTc interval was studied as a continuous variable in the analysis to increase power and avoid choosing cut-off points. A P-value <0.05 was considered significant.
RESULTS
Five hundred and thirty-six intravenous drug user patients were monitored between August 2012 and January 2013 at CAS Barceloneta, 139 of whom were HIV-infected.
Of these HIV patients, 6 were not receiving methadone, 24 had a positive toxicologic urine test, 13 had data missing for inclusion in the analysis and 5 had heart disease.
Finally, 91 patients were included in the study. The clinical characteristics of the HIV patients included in the study are shown in Table 1 .
Sixty-eight of 91 (74.7%) HIV patients were on HAART, and viral load HIV-1-RNA <20 copies/mL was observed in 67 of the 68 (98.5%) patients.
Median methadone doses were 70 (15-250) mg/day, and 28/91(30.7%) patients were receiving methadone doses higher than100 mg/day.
Compensated hepatitis C-induced cirrhosis was present in 11/84 (13%) co-infected hepatitis C patients and all were taking boosted PI.
QTc-prolonging medications were used in 53/91 (58.2%) patients: antipsychotics in 34 patients, antidepressants in 26, antiepileptics in 12 and antibiotics in 5.
Prolonged QTc interval QTc (QTc>450 ms) was documented in 33/91(36.3%) patients with no sex-related differences (P 0.893) and 3/91 (3.2%) patients had QTc >500 ms.
Comparison of the QTc interval according to clinical variables is shown in Table 2 .
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Methadone maintenance treatment has been shown to be medically safe in many prospective studies in the management of opioid dependence, and clinical guidelines on QTc screening exist for patients on methadone maintenance therapy (21, 22) .
However, cases of prolongation of the QTc interval and Torsades de Pointes have been reported, particularly in patients receiving higher doses of methadone (13) (14) (15) . As with the results observed in HIV-negative patients (20, (31) (32) (33) , a dose-dependent relationship between methadone and QTc interval prolongation was observed in our patients. This finding has significant clinical implications, since higher methadone doses are more effective than lower doses in retaining patients and in reducing heroin and cocaine use during treatment (32) ; however the risk of prolonged QTc interval is increased.
A further interesting topic of concern is the contradictory effect of antiretroviral therapy on QTc interval duration. Although PIs inhibit hERG current in vitro (11) and therefore are expected to prolong the duration of ventricular repolarization, we found no relationship between PI or NNRTI intake and QTc prolongation, in agreement with recent HIV cohort studies (24) (25) (26) (27) (28) . Theoretical models suggest that such a degree of hERG blockade is expected to produce a prolongation of the QTc interval of <5 ms (34) . This could explain the lack of a significant influence of PI on QTc prolongation in This clinical finding is important since the prevalence of hepatitis C virus (HCV) among intravenous drug users with HIV infection is close to 90%, and hepatitis C liver disease is an increasingly recognized cause of morbidity and mortality in these individuals (37) .
In addition to methadone, other drugs can prolong the QT interval by blocking hERGencoded potassium channels, or some drugs can act by modifying sodium channels (4).
Our study showed a non-significant trend towards the use of QT-prolonging medications, probably due to the fact that we classified all drugs with effects on the QTc interval in the same categorical group, including those with different risks of prolonging the QTc interval. Furthermore, the small sample size of the study may have produced underestimation of the results. Nevertheless, as our study shows, the wider use of other drugs with effects on the QTc interval in this HIV patient group is noteworthy and highlights the importance of reviewing the use of concomitant medication for the treatment of co-morbidities in opioid-dependent HIV patients (4, 38) and, particularly potential interactions between antiretroviral drugs and drugs with known QTc intervalprolonging effects. This is interesting to note since several antiretroviral drugs exhibit inhibitory and/or inducing effects on cytochrome P450 isoenzymes which are A c c e p t e d M a n u s c r i p t 10 responsible for the metabolism of many medications and, consequently, could greatly increase the plasmatic concentration of QTc-prolonging medications and, secondarily the risk of prolonging QTc.
Together with the high prevalence of prolonged QTc interval in HIV patients on methadone maintenance therapy, the clinical implications of prolonged QTc include the increased risk of cardiovascular disease and mortality (39) . As seen in HIV-seronegative patients, the results of the SMART trial proved the significance of ECG abnormalities in the development of cardiac events in a well-defined multi-racial population who were cardiovascular disease-free at study baseline. In the multi-adjusted model, HIV patients with prolonged QTc had a six-fold greater risk of a cardiovascular event than HIV patients with normal-interval QTc (25) . Hypothetically, the cardiovascular risk associated with a prolonged QTc interval may be higher in HIV patients on methadone maintenance therapy since this HIV patient group have more prevalent risk factors associated with prolonged QTc interval (advanced HIV disease, liver cirrhosis, concomitant use of drugs that prolong the QTc interval) (40) than patients included in the SMART trial.
Buprenorphine and morphine are opiate derivates with comparable efficacy to methadone for opioid dependence. They block the hERG channel with notably less potency than methadone and may constitute a safe alternative in HIV patients on methadone maintenance therapy with an increased risk of a prolonged QTc interval (41) .
Despite the statistical limitations due to the small sample size and the observational nature of the study, patients with different methadone doses and those on antiretroviral therapy were included in the analysis so that the sample would be representative of this specific HIV patient group. Moreover, the results achieved concur with those published in the literature.
In conclusion, the prevalence of prolonged QTc interval in opioid-dependent HIVinfected patients on methadone maintenance therapy is high; in fact, one in three patients may have a prolonged QTc interval. Risk factors for prolongation of the QTc interval are liver cirrhosis, higher methadone doses and antiretroviral-naive therapy.
Clinicians should be aware of the risk of a prolonged QTc interval and the need for ECG monitoring in this specific HIV patient group so that cardiovascular morbidity and mortality can be minimized. 
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